Johnson & Johnson Vision leader explains significance of latest IOL milestone

Johnson & Johnson Vision received FDA approval for its Tecnis PureSee intraocular lens (IOL), designed to provide patients with an extended depth of focus and clear vision with minimal visual disturbances. Peter Menziuso, Company Group Chair, Vision, Johnson & Johnson, emphasized that this IOL is the first and only EDOF IOL in the U.S. without a warning on loss of contrast sensitivity, offering a significant advancement in cataract care. He highlighted the importance of personalized options for patients and surgeons, expanding the Tecnis platform to address a wide range of visual needs.